Get Adobe Flash player
Diabetes 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37. 38. 12 Brunton SA, Nocturnal hypoglycemia: answering the challenge with long-acting insulin analogs, MedGenMed, 2007;9:38. Brod M, Rana A, Barnett AH, Impact of self-treated hypoglycaemia in type 2 diabetes: a multinational survey in patients and physicians, Curr Med Res Opin, 2012;28:1947–58. Brod M, Christensen T, Bushnell DM, Impact of nocturnal hypoglycemic events on diabetes management, sleep quality, and next-day function: results from a four-country survey, J Med Econ, 2011;15:77–86. Brod M, Christensen T, Thomsen TL, et al., The impact of non- severe hypoglycemic events on work productivity and diabetes management, Value Health, 2011;14:665–71. Brod M, Christensen T, Bushnell DM, The impact of non-severe hypoglycemic events on daytime function and diabetes management among adults with type 1 and type 2 diabetes, J Med Econ, 2012;15:869–77. Wright RJ, Frier BM, Vascular disease and diabetes: is hypoglycaemia an aggravating factor?, Diabetes Metab Res Rev, 2008;24:353–63. Zoungas S, Patel A, Chalmers J, et al., Severe hypoglycemia and risks of vascular events and death, N Engl J Med, 2010;363:1410–18. Frier BM, Schernthaner G, Heller SR, Hypoglycemia and cardiovascular risks, Diabetes Care, 2011;34 Suppl. 2:S132–7. Johnston SS, Conner C, Aagren M, et al., Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetes, Diabetes Care, 2011;34:1164–70. Bonds DE, Miller ME, Bergenstal RM, et al., The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study, BMJ, 2010;340:b4909. Whitmer RA, Karter AJ, Yaffe K, et al., Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mel- litus, JAMA, 2009;301:1565–72. Tobin GS, Cavaghan MK, Hoogwerf BJ, et al., Addition of exenatide twice daily to basal insulin for the treatment of type 2 diabetes: clinical studies and practical approaches to therapy, Int J Clin Pract, 2012;66:1147–57. Heine RJ, Van Gaal LF, Johns D, et al., Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial, Ann Intern Med, 2005;143:559–69. Buse JB, Rosenstock J, Sesti G, et al., Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD- 6), Lancet, 2009;374:39–47. Nayak UA, Govindan J, Baskar V, et al., Exenatide therapy in insu- lin-treated type 2 diabetes and obesity, QJM, 2010;103:687–94. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. 51. Viswanathan P, Chaudhuri A, Bhatia R, et al., Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin, Endocr Pract, 2007;13:444–50. Yoon NM, Cavaghan MK, Brunelle RL, et al., Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting, Clin Ther, 2009;31:1511–23. Lind M, Jendle J, Torffvit O, et al., Glucagon-like peptide 1 (GLP-1) analog combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction, Prim Care Diabetes, 2011;6:41–6. Iyer SN, Tanenberg RJ, Mendez CE, et al., Pancreatitis associated with incretin-based therapies, Diabetes Care, 2013;36:e49. Wang F, Surh J, Kaur M, Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review, Diabetes Metab Syndr Obes, 2012;5:191–204. Jonassen I, Havelund S, Hoeg-Jensen T, et al., Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin, Pharm Res, 2012;29:2104–14. Heise T, Nosek L, Bottcher SG, et al., Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes, Diabetes Obes Metab, 2012;14:944–50. Garber AJ, King AB, Del Prato S, et al., Insulin degludec, an ultra- longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to- target non-inferiority trial, Lancet, 2012;379:1498–507. Ratner RE, Gough SC, Mathieu C, et al., Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials, Diabetes Obes Metab, 2012;15:175–84. Niskanen L, Leiter LA, Franek E, et al., Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial, Eur J Endocrinol, 2012;167:287–94. Mathieu C, Hollander P, Miranda-Palma B, et al., Efficacy and Safety of Insulin Degludec in a Flexible Dosing Regimen vs Insulin Glargine in Patients With Type 1 Diabetes (BEGIN: Flex T1): A 26-Week Randomized, Treat-to-Target Trial With a 26-Week Extension, J Clin Endocrinol Metab, 2013;98(3):1154–62. Meneghini L, Atkin SL, Gough SC, et al., The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same Time Daily: A 26-week, randomized, open-label, parallel-group, treat-to-target trial in people with type 2 diabetes, Diabetes Care, 2013;36(4):858–64. Pandyarajan V, Weiss MA, Design of non-standard insulin analogs for the treatment of diabetes mellitus, Curr Diab Rep, 52. 53. 54. 55. 56. 57. 58. 59. 60. 61. 62. 63. 2012;12:697–704. Bergenstal RM, Rosenstock J, Arakaki RF, et al., A randomized, controlled study of once-daily LY2605541, a novel long- acting basal insulin, versus insulin glargine in basal insulin- treated patients with type 2 diabetes, Diabetes Care, 2012;35:2140–47. Rosenstock J, Bergenstal RM, Blevins TC, et al., Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes: A randomized, crossover study, Diabetes Care, 2013;36:522–8. Sheffield CA, Kane MP, Busch RS, et al., Safety and efficacy of exenatide in combination with insulin in patients with type 2 diabetes mellitus, Endocr Pract, 2008;14:285–92. Arnolds S, Dellweg S, Clair J, et al., Further improvement in post- prandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study, Diabetes Care, 2010;33:1509–15. Buse JB, Bergenstal RM, Glass LC, et al., Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial, Ann Intern Med, 2011;154:103–12. Thong KY, Jose B, Sukumar N, et al., Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit*, Diabetes Obes Metab, 2011;13:703–10. DeVries JH, Bain SC, Rodbard HW, et al., Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets, Diabetes Care, 2012;35:1446–54. Fonseca V, Schweizer A, Albrecht D, et al., Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes, Diabe- tologia, 2007;50:1148–55. Bruttomesso D, Pianta A, Mari A, et al., Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients, Diabetes, 1999;48:99–105. Holleman F, Schmitt H, Rottiers R, et al., Reduced frequency of severe hypoglycemia and coma in well-controlled IDDM patients treated with insulin lispro. The Benelux-UK Insulin Lispro Study Group, Diabetes Care, 1997;20:1827–32. Home PD, Lindholm A, Riis A, et al., Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial, Diabet Med, 2000;17:762–70. Woerle H-J, Neubacher, D, Patel, S, et al., Safety and Efficacy of Linagliptin Plus Basal Insulin Combination Therapy in a vulner- able Population of Elderly Patients (Age ≥70 Years) With Type 2 Diabetes, 48th Annual Meeting of the European Association for the Study of Diabetes, Berlin, Germany, Poster P848, 2012. US E ndocrinology